Quest Diagnostics and Lisata Therapeutics are working together on a research project to find a better way to test for cancer. They will use a special technology called Haystack MRD, which can detect very small amounts of cancer DNA in the blood. This can help doctors know if a new treatment is working or not. They will test their idea on people with a type of pancreas cancer that is hard to treat. This research could help make new medicines and better ways to test for cancer in the future. Read from source...

- The article is not a proper research report, but more of a promotional piece for Quest Diagnostics and its subsidiaries, as well as Lisata Therapeutics.
- The article is full of inconsistencies, such as:
- The image URL should start with "https://cdn.benzinga.com/", but it starts with "https://cdnwp-s3.benzinga.com/", which is a different domain.
- The article states that the Haystack MRD test was oversubscribed with nearly 20 leading cancer institutions, but then mentions that DGX completed the validation of the test in March 2024. This implies that the validation was done before the test was oversubscribed, which doesn't make sense.
- The article states that the FORTIFIDE study is investigating the safety, tolerability, and efficacy of certepetide plus chemotherapy, but then mentions that certepetide is an investigational treatment for metastatic pancreatic cancer. This implies that certepetide is not yet approved for any use, which contradicts the previous statement.
- The article states that Lisata Therapeutics is a clinical-stage pharmaceutical company, but then mentions that it expects to announce several clinical studies and business achievements over the next two years and projects that its available capital will fund operations into early 2026. This implies that the company is not likely to advance to the next stage of development anytime soon, which contradicts the previous statement.
- The article is biased in favor of Quest Diagnostics and its subsidiaries, as well as Lisata Therapeutics, by:
- Using positive and favorable terms and phrases, such as "partnership", "collaboration", "research", "innovative therapies", "investigational treatment", etc.
- Providing optimistic and exaggerated estimates and projections, such as the MRD testing market being expected to witness a CAGR of 14% by 2027, or the Haystack MRD test being expected to launch nationwide later this year.
- Ignoring or downplaying the risks and challenges associated with the MRD technology and the clinical trials, such as the lack of early diagnosis or limited patient response to treatments, or the competitive landscape and regulatory hurdles.
- Emphasizing the benefits and potential of the MRD technology and the clinical trials, such as the ability to detect and analyze ctDNA with exceptional sensitivity, or the opportunity to drive forward the development

All investments carry risks, and it's important for investors to carefully consider these risks before investing. High-growth stocks and stocks with significant growth potential often carry higher risks, while lower-growth stocks and stocks with more stable growth potential tend to carry lower risks.